Company / Operating Cash Flow
AGIOS PHARMACEUTICALS, INC. Operating Cash Flow History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
-$373.0M
FY2025
5-year range
-$407.3M / -$290.8M
FY2021-FY2025
Trend
+4.3%
vs FY2024
Sector context
#201 of 216
Health Care
What the data says
Among 216 Health Care companies, AGIOS PHARMACEUTICALS, INC. is in the bottom 7% for operating cash flow. Operating Cash Flow returned to growth in FY2025 after 2 years of decline, reaching -$373M.
Based on SEC 10-K filings.
-$373M in FY2025.
Declined from -$296M to -$373M over the past 2 years.
Health Care sector context is included.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 7% in Health CareTop 93% of 216This company -$373.0M Sector average $659.0M
▼
-156.6% below sector average
Key checks
Key Insights
- In FY2025, operating cash flow increased 4.3% year-over-year.
- Ranks #201 out of 216 companies in the Health Care sector.
- Peak operating cash flow was recorded in FY2018.
- Lowest operating cash flow in the period was in FY2021.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 3.83 (safe zone, above 2.9 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$373.0M | +4.3% |
| FY2024 | -$389.8M | -31.7% |
| FY2023 | -$296.1M | -1.8% |
| FY2022 | -$290.8M | +28.6% |
| FY2021 | -$407.3M | -33.8% |
| FY2020 | -$304.4M | +17.9% |
| FY2019 | -$370.6M | -1061.1% |
| FY2018 | $38.6M | +113.5% |
| FY2017 | -$285.2M | -839.7% |
| FY2016 | $38.6M | +168.4% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026